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Abstract
Purpose
To correlate the differentially expressed miRNAs with clinico-pathological features in uveal
melanoma (UM) tumors harbouring chromosomal 3 aberrations among South Asian Indian
cohort.
Methods
Based on chromosomal 3 aberration, UM (n = 86) were grouped into monosomy 3 (M3; n =
51) and disomy 3 (D3; n = 35) by chromogenic in-situ hybridisation (CISH). The clinico-patho-
logical features were recorded. miRNA profiling was performed in formalin fixed paraffin
embedded (FFPE) UM samples (n = 6) using Agilent, HumanmiRNAmicroarray, 8x15KV3
arrays. The association betweenmiRNAs and clinico-pathological features were studied
using univariate andmultivariate analysis. miRNA-gene targets were predicted using Target-
scan and MiRanda database. Significantly dys-regulatedmiRNAs were validated in FFPEUM
(n = 86) andmRNAs were validated in frozen UM (n = 10) by qRT-PCR. Metastasis free-sur-
vival and miRNA expressions were analysed by Kaplen-Meier analysis in UM tissues (n = 52).
Results
Unsupervised analysis revealed 585 differentially expressed miRNAs while supervised
analysis demonstrated 82 miRNAs (FDR; Q = 0.0). Differential expression of 8 miRNAs:
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miR-214,miR-149*,miR-143,miR-146b,miR-199a, let7b,miR-1238 andmiR-134 were
studied. Gene target prediction revealed SMAD4,WISP1, HIPK1, HDAC8 and C-KIT as the
post-transcriptional regulators ofmiR-146b,miR-199a,miR-1238 andmiR-134. Five miR-
NAs (miR-214,miR146b,miR-143,miR-199a andmiR-134) were found to be differentially
expressed in M3/ D3 UM tumors. In UM patients with liver metastasis,miR-149* andmiR-
134 expressions were strongly correlated.
Conclusion
UM can be stratified using miRNAs from FFPE sections. miRNAs predicting liver metastasis
and survival have been identified. Mechanistic linkage of de-regulated miRNA/mRNA
expressions provide new insights on their role in UM progression and aggressiveness.
Introduction
Uveal Melanoma (UM) is a primary adult intraocular tumor. The prevalence of UM is 0.02%
in South Asian Indian populations [1]. According to Collaborative Ocular Melanoma Study
group (COMS, 2001), about 50% of UM patients develop liver metastasis within 10–15 years of
enucleation [2]. UM diagnosis and hepatic metastasis prediction is critical in prognosis and
planning therapeutic regimes [3,4]. The existing prognostic factors include clinical parameters,
histopathological parameters, extra-ocular extension, immune-markers, chromosomal aberra-
tions (1, 6, 8, 13q and 16p) and germ line mutations (BAP1 and GNA11/ GNAQ) [1,5,6,7].
Extensive molecular studies using gene expression and chromosomal aberration analysis
have helped to stratify UM into 2 classes—class 1 tumors with low risk of liver metastasis, asso-
ciated with disomy3 (D3), and class 2 tumors with high risk of liver metastasis associated with
monosomy3 (M3) [8]. Unfortunately, there is a lack of accuracy in the molecular genetic test-
ing due to intra-tumoral heterogeneity [9] and micro-deletions of genes prevailing in UM
tumors decreasing the precision in identifying micro-metastases [10].
MicroRNAs (miRNAs) are non-coding RNAs that regulate the gene expression at the post-
transcriptional stage and they play an important role in tumor progression and metastasis.
miRNAs based biomarkers are gaining importance in cancer diagnosis and for prognosis
[11,12]. There are a few earlier studies on miRNA profiles in UM. In one study, miRNA pro-
files in UM have been studied using primary tumor tissues, primary cells and cell lines
[13,14,15]. In the second study, 6 miRNAs (let-7b,miR-199a,miR-199a,miR-143,miR-193b,
and miR-652) were identified to differentiate class 1 and class 2 UM tumors [13]. In the third
study, prognostic significance of chromosome 3 loss and 8q gain was observed in UM archival
samples, however a clear correlation was not observed between miRNA expression with metas-
tasis and survival [16].
In India, majority of the melanomas are enucleated by the ophthalmologist and a small frac-
tion of the patients who are treated at tertiary referral eye centre also have opportunity for plaque
therapy [17]. Currently, much emphasis is laid on the largest tumor diameter (LTD) and a few
centres do offer in-situ hybridisation (CISH) basedM3 detection [18]. Here, we explored the
potential of miRNAs as in UMwith M3/D3, and their association with liver metastasis in South
Asian Indian cohort of uveal melanomas. The merits of the present study are the availability of
the clinico-pathological records along with the corresponding formalin-fixed paraffin embedded
(FFPE) melanoma tissues for miRNA analysis. FFPE samples can be used for miRNA expression
analysis as the secondary structures are not altered even after fixation processes [19].
miRNAs in UM with Chromosome 3 Aberrations
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Materials and Methods
Sample collection
FFPE eyeballs (n = 86) diagnosed as UM at Medical Research Foundation, Sankara Nethralaya,
(2009–2013) were included in the study. Duly signed consent forms from the patient/guardian
as a part of clinical management were obtained from enrolled patients. Normal melanocytes
(n = 5) were collected from the human cadaveric eyeballs received at CU Shah Eye bank
(http://www.sankaranethralaya.org/eye-bank.html) during 2011–2012. The study was reviewed
and approved by the local ethics committee at Vision Research Foundation, Sankara Nethra-
laya and the committee deemed that it conformed to the principles of research, in accordance
with Helsinki Declaration (Ethics number: 146b-2009-P).
Specimen selection
Clinico-pathological features. Study cohort included 58 male and 28 female patients with
the median age of 48.5 years. The study group consisted of 12 patients diagnosed with ciliary
body melanoma and 74 with choroidal melanoma. Mean of the largest tumor diameter (LTD)
was 13.7mm X 9.6mm. Haematoxylin and Eosin slides were reviewed and 1–2 representative
tumor tissue blocks were selected. History of liver metastasis was obtained from patient medi-
cal records. The study included UM tumors with cell types: spindle cells (n = 27), epitheliod
(n = 15) and mixed cell type (n = 44). These 86 UM tumors includes 37 UM with scleral exten-
sion; 8 UM with extension into vortex veins and 11 UM with extension into orbit. The 52
patients (60.46% corresponding to 52/86 cohort) with 2–5 years of follow-up were considered
for the metastasis-free survival analysis (Kaplen-Meier). The clinical follow-up study revealed
17 patients diagnosed with liver metastasis. The clinico-pathological variables (age, sex, speci-
men obtained, cell type and LTD) provided as S1 Table.
Chromogenic in-situ hybridisation. Centromeric probes (Invitrogen, USA) were used to
detect chromosome 3 aberrations and disomy 18 (control). Hybridisation and scoring proto-
cols were followed as reported earlier [18].
Immunohistochemistry. Immunohistochemical detection of HSP27 on FFPE tumor sec-
tions was performed by using a rabbit polyclonal antibody (AM171-10M, Biogenex, CA, USA),
Super Sensitive TM Polymer- HRP detection system (Biogenex, CA, USA) and aminoethyl car-
bazole according to the manufacturer’s instructions. Breast cancer cell line (MCF-7) served as
positive control [20]. The immune-score ranges from 0–12 [21].
miRNA profiling. Three M3 and three D3 uveal melanoma tumors were taken for expres-
sion studies. The study was carried out using technical duplicates. The small RNA was
extracted from the FFPE tissues using miRVANA kit (Ambion, Life Technologies, USA) fol-
lowing manufacturer’s protocol. The processed samples were hybridized on the Human
miRNA microarray, 8x15KV3 array as per manufacturer’s instruction. The microarray slide
was scanned using Agilent Scanner (Agilent Technologies, Part Number G2565CA).
qRT-PCR. Total RNA was isolated from FFPE tissues using Recover All™ total nucleic
acid isolation (Ambion, Life technologies, USA) as per manufacturer’s protocol. Reverse tran-
scription (RT) of mature miRNA in 100 ng/μl of total RNA using TaqMan MicroRNA RT kit
(Applied Biosystems, Foster City, CA) was carried out following manufacturer’s protocol. For
gene expression studies, RT was carried out using oligo dT random primers and Sensiscript II
kit (205211, Qiagen, Santa Clara, CA). Real-time PCR was performed using 1X Universal PCR
Master Mix, taqman miRNA probes (ABI Applied Biosystem, USA) and 1X Universal RT2
Real Time ™ SyBr Green/ROX PCR master Mix (Catalogue No: 330520, SABiosciences, USA)
miRNAs in UM with Chromosome 3 Aberrations
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according to the manufacturer’s instructions. Description of taqman probes and primers were
tabulated (S2 Table). The unit expression is log2 transformed ratios.
Statistical analysis
qRT- PCR data analysis. The miRNA expressions were derived after normalizing with the
mean expression of normal melanocytes (n = 5). Cut-offs used for de-regulation in miRNA
expression was: greater than 1(log2 ratio) as positive expression and less than—0.5 (log2 ratio)
as negative. Pearson’s correlation, chi-square test, independent student‘s-t test and ANOVA
were used to derive the significance between the variables. Paired student’s-t test was used to
derive the significance among miRNA expressions between M3/D3 tumors. Kaplen-Meier’s
test was used to assess the survival rates for the presence of eight miRNAs.
Microarray analysis. Cut-offs used for de-regulation in miRNA expression was: greater
than 1 (log2 transformed value) in M3 detected tumors and less than 1 (log2 transformed
value) in chromosome 3 balanced tumors. ANOVA was used to identify the highly expressed
miRNA in the M3 tumors compared with D3 tumors. Significance Analysis of Microarray
(SAM) was performed to derive the significant miRNAs (Q = 0.0). Experimentally validated
targets for the differentially expressed miRNAs were obtained from TargetScan, MiRanda and
miRTarbase. Further, they were subjected to GO and Pathway enrichment analysis using PAN-
THER data base with p-value cut-off 0.05 along with Boneferroni FDR correction. Down-
stream effects analysis was performed to identify the biological processes and functions that are
likely to be causally affected by identified regulated genes. We used the Ingenuity Pathway
Analysis (IPA, Ingenuity1 Systems) regulation z-score algorithm to identify biological func-
tions that are expected to be more active in UM (increased—positive z-score) and less active
(decreased—negative z-score). The p-value was calculated using the Fischer's exact test and
reflects the likelihood that the association between a set of genes/miRNAs in our dataset and a
biological function is significant (p-value 0.05).
Results and Discussion
Grouping of UM into monosomy of chromosome 3 (M3) / disomy of
chromosome 3 (D3)
Chromosome 3 loss was detected in 59.30% [51/86] of UM, and presence of both the copies of
chromosome 3 was detected in 40.69% [35/86] UM using chromogenic in-situ hybridisation
(CISH). Among the UM which had metastasized to liver (n = 17), M3 was detected in 64.7%
[11/17] and D3 was detected in 35.29% [6/17] UM (S1 Fig). Here, emphasis was laid on the
observation of D3 in UM that had metastasized to the liver. Existence of intra-tumoral hetero-
geneity in UM [9] might have contributed to this variation in metastatic prediction.
Based on an earlier report, UM were further grouped in to M3/D3 by analysing the expres-
sion of Heat shock protein 27 (HSP27) protein using immunohistochemistry [21]. S1 Table
indicates the distribution of HSP27 protein expression in UM. Photomicrographs reveal the
cytoplasmic positivity of HSP27 expression in UM sections (S2 Fig). A significant association
was observed between HSP27 expression and M3 (p-value = 0.021) as indicated earlier [21].
Clinico-pathological descriptions of tumors, hybridization scores and immuno-scores for indi-
vidual UM are tabulated in S1 Table. Their statistical significance with M3 and liver metastasis
are indicated in S3 and S4 Tables. A significant association of M3 to tumor base (p = 0.002)
was observed.
miRNAs in UM with Chromosome 3 Aberrations
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Selection of significantly dys-regulated miRNAs using a high throughput
analysis
The miRNAs were filtered using unsupervised and supervised data analysis. The common pool
of miRNAs thus obtained was selected for validation by qRT-PCR. Data of miRNA profiling
has been submitted to GEO database (GSE68828).
Data analysis of miRNA profiling
In unsupervised analysis, Principal Component Analysis (PCA) revealed clustering of three
M3 UM tumors forming a single group and correlated with the CISH based classification. The
slight difference within the D3 UM tumors could be due to the heterogeneity in the tumor infil-
trating lymphocytes and the cell type (Fig 1A). The miRNA profiling of the tumors (n = 6)
revealed a total of 585 differentially expressed miRNAs between M3 (n = 3) and D3 (n = 3)
Fig 1. Unsupervised and supervised analysis of miRNA expression in UM. A: Graphical representation of the unsupervised analysis: principal
component analysis (PCA) for the UM tumor tissues: M3 (n = 3), and D3 (n = 3) showing the clustering of samples correspondingly in to two distinct groups
(M3 and D3). Blue colored triangle denotes M3 UM tumors while red colored spheres denotes D3 UM tumors. B: Supervised analysis: The significance
analysis of microarray (SAM) plot reveals the de regulated miRNAs between the monosomy and disomy formalin fixed UM primary tumors. The false
discovery rate (FDR) has set at Q = 0.78%. The list of miRNAs with Q = 0.0 has been considered for the validation by qRT-PCR. C: Venn diagram on
intersection of miRNAs obtained from ANOVA and SAM.miR-134,miR-1238,miR-149* are the common select miRNAs observed from this study.
doi:10.1371/journal.pone.0146128.g001
miRNAs in UM with Chromosome 3 Aberrations
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samples. S3 Fig shows the hierarchical cluster for the top 100 differentially expressed miRNAs
with p<0.05. Data analysis using ANOVA listed 25 up-regulated miRNAs and 26 down-regu-
lated miRNAs in M3 tumors relative to D3 tumors. (S5 Table shows top 10 miRNAs).
In supervised analysis, SAM, we observed 82 differentially expressed miRNAs with the false
discovery rate (FDR); Q = 0.0 (Fig 1B). Top 10 up-regulated miRNAs with maximum score
and high fold change were:miR-317-5p,miR-373,miR-1268,miR-191,miR-150,miR-1275,
miR-188-5p,miR-1238,miR-134 andmiR-296-5p.
On intersection of miRNAs detected in both ANOVA and SAM analysis here, we observed
14 up-regulated miRNAs in common (Fig 1C). Absolute expression levels of key miRNAs iden-
tified to be differentially expressed by ANOVA and SAMmethods showed (Fig 2A) discriminat-
ing profiles in M3 and D3 tumors, indicating the sensitivity of detection. Further, these key
miRNAs subjected to unsupervised hierarchical clustering clearly identified miRNA clusters
that could indicate co-expression pattern across M3 and D3 tumors (Fig 2B). Analysis of key
gene ontology (GO) and pathways regulated by the differentially expressed miRNAs were iden-
tified by ways of genes that are validated and to be targeted by these miRNAs. Some of the GO
and pathways targeted by these differentially expressed miRNAs includeWnt signaling; angio-
genesis and p53 pathway (Fig 2C). Since, dys-regulation of p53 pathway has been reported in
UM earlier [22], we explored the miRNAs and their targets and subjected to regulatory network
modeling to understand the differential regulation of p53 pathway in M3 and D3 UM tumors.
miRNAs expression in UM using qRT-PR
Three miRNAs:miR-149,miR-1238 andmiR-134 (which were in common with supervised
and unsupervised data analysis; Fig 1C) and 5 miRNAs:miR-214,miR-143,miR146b,miR-
199a and let7b (earlier shown as class 1/ class 2 discriminators) [13] were selected for valida-
tion. Also, the analysed expressions were associated with M3, D3 and liver metastasis in UM.
AmongM3 UMwith liver metastasis (n = 11), higher expressions ofmiR-149 (72.72%),
miR-1238 (100%),miR-134 (100%),miR-214 (54.54%),miR-146b (54.54%),miR-199a (100%)
while moderate expression ofmiR-143 (45.45%) and negative expression of let-7b (100%) was
observed. AmongM3 UMwith no history of liver metastasis (n = 40), higher expressions of
miR-149 (90.0%),miR-1238 (97.5%) andmiR-134 (57.5%),miR-214 (62.5%),miR-146b (67.5%),
miR-143 (65.0%),miR-199a (90.0%) and lower expression of let-7b (30.0%) were observed.
Among D3 UM with liver metastasis (n = 6), higher expressions ofmiR-149 (83.3%),miR-
1238 (83.3%),miR-199a (100%); moderate expressions inmiR-134 (50%),miR-214 (50.0%),
while lower expressions ofmiR-146b (33.33%) and let-7b (25%) and negative expression in
miR-143 (100%) were observed. Among D3 UM with no liver metastasis (n = 29), higher
expressions ofmiR-149 (72.41%),miR-1238 (86.2%),miR-199a (82.75%),miR-134 (41.37%),
miR-214 (41.37%) andmiR-146b (58.62%), while lower expression ofmiR-143 (37.93%), let-7b
(13.79%) were observed (S6 Table and Fig 3). Relative miRNA expressions quantified by
qRT-PCR in UM tumors are indicated as S7 Table.
Glycogen synthase kinase-3α (GSK-3α), a known gene target ofmiR-149 is an important
melanoma growth regulator [23,24].MiR-1238 is known to regulate SASH1 (SAM and SH3
domain-containing protein 1, a tumor suppressor gene), contributing to breast cancer aggres-
siveness [25]. AlthoughmiR-1238 expression among the two UM groups were not significant, a
higher percentage ofmiR-1238 (94.18%) suggests its possible role in uveal melanoma tumori-
genesis.miR-134 is associated with invasiveness and metastasis in other cancers [26] with the
putative gene targets such as VEGFA, FOXM1,MYCN, CD9 andWWOX1 genes [26,27,28]. In
the present study, higher percentage ofmiR-134 (94.11%) in UMwith liver metastasis, irrespec-
tive of chromosome 3 aberrations, suggests it could be a potential biomarker for class 2 tumors.
miRNAs in UM with Chromosome 3 Aberrations
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Fig 2. Significantly dys-regulatedmiRNAs and pathways in UM. A: Trendline graph shows the absolute
expression of key miRNAs identified by ANOVA and SAM. The differentially expressed miRNAs indicates the
discriminating profiles in M3 and D3 UM tumors. The blue line indicates the miRNA expression in D3 UM
miRNAs in UM with Chromosome 3 Aberrations
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Among the five miRNAs previously shown as class 2 tumor discriminators [13], four up-
regulated miRNAs (miR-214,miR-143,miR-146b and miR-199a) showed a significant associa-
tion with M3 tumors while the other miRNA, let-7b did not show any significant association
with M3 UM (Fig 3).miR-214 regulates cell cycle regulatory genes: phosphatase and tensin
homolog (PTEN) [29], adipocyte protein 2 (AP2) and tumour protein 53 (TP53) genes [30].
miR-143 is known for its oncogenic activity together with KRAS (Kirsten rat sarcoma viral
oncogene homolog), NF-kB (Nuclear factor kappa B) genes in cancers [31,32].miR-146b, is
known for its oncogenic role in UM cells [33] with its reported gene targets NF-kB and SMAD4
(Mothers against decapentaplegic Homolog 4). Deregulation of NF-kB pathways is known to
regulate UMmetastasis [34].
Interestingly,miR-199a, another regulator of SMAD4 was also up-regulated in the present
study (S6 Table). The tumorigenic role of this miRNA is substantiated by earlier reports in UM
[13]. Let 7b, a known tumor suppressor miRNA is down-regulated in various cancers namely
tumors while red line indicates the miRNA expression in M3 tumors. B: Hierarchical cluster shows key
miRNAs subjected to unsupervised analysis. The differentially expressedmiRNAs indicates the co-
expression pattern across M3 and D3 UM tumors. The green colour indicates the down-regulated miRNAs
while the red colour indicates the up-regulated miRNAs in M3 and D3 UM tumors. C: Analysis of key gene
ontology (GO) and Pathway Enrichment by the differentially expressed miRNAs. A few of the pathways (i)
and GO (ii and iii) targeted by these differentially expressed miRNAs using miRTarbase and PANTHER data
base with p-value cut-off0.05 along with Boneferroni FDR correction.
doi:10.1371/journal.pone.0146128.g002
Fig 3. Graphical representation of the miRNA expression (fold change in log 2 ratio) in M3 / D3 UMs derived using Graph pad Prism. The dotted line
represents the mean fold change of miRNA expressions while "M" denotes the mean fold change of the respective miRNA expression in UM groups.
doi:10.1371/journal.pone.0146128.g003
miRNAs in UM with Chromosome 3 Aberrations
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acute lymphoblastic leukaemia [35] and retinoblastoma [36]. Restoration of let-7b is consid-
ered as a potential therapeutic option in cancers [37]. Earlier, let-7, has been stated as a strong
significant discriminator in primary UM [13] while let-7b is reported at low levels in OCM1
cells [15]. Here, we observed let-7b de-regulation in the present UM cohort.
Validation of target genes regulated by select miRNAs in UM
Earlier, Harbour et al have reported a PCR based platform (DecisionDx-UM) consisting of 15
genes list to measure the risk stratification of UM tumors [4,38]. However, the additional prog-
nostic factors specific to UM tumors such as cytogenetic analysis and miRNA expressions
would confirm the uveal melanoma risk stratification [39]. Here, we have explored gene targets
of select miRNAs to implicate miRNA/mRNA’s role in UM progression. Downstream analysis
(S8 Table) revealed the role of up-regulated miRNAs, their regulated genes in apoptotic and
cell signalling pathways. Further, gene targets prediction of the differentially expressed miR-
NAs revealed the negative regulation of gene lists namely (i) SMAD4,WISP1,HDAC8 and
C-KIT bymiR-146b, (ii)WISP1 bymiR-1238,miR-134 and (iii) SMAD4 bymiR-199a (Fig 4).
Among these interactions, we observed SMAD4 and WISP1 as the common regulators.
SMAD4 andWISP1 are known to regulate p53 pathway [40,41]. Infrequent mutation of p53
pathway is reported in melanoma [22]. Thus, the down-regulation of SMAD4 gene and varied
expression ofWISP1 gene (S9 Table) substantiates the varied activation of p53 pathway in UM.
Here, inactivation of p53 pathway in UMwas supported by the over-expression ofHIPK1 gene
(S9 Table) which corroborates with an earlier report in other cancer (colorectal cancer) [42]. Fur-
ther, we observed the de-regulation ofHDAC8 and C-KIT genes, the known targets ofmiR-146b
[43]. The role of these target genes needs further investigations. Thus, the elevated level of these
miRNAs together with its target genes suppression might contribute to the UM aggressiveness.
Fig 4. Network interaction between the dysregulated miRNAs and their gene targets in UM. A: D3 UM tumor; B: M3 UM tumor. The network is drawn
with the expressions obtained by qRT-PCR using cytoscape v.2.8. Green colour indicates the down-regulation of miRNAs/ genes; red colour indicates the
up-regulation of miRNAs/ genes; Yellow colour indicates varied miRNA/ gene expression.
doi:10.1371/journal.pone.0146128.g004
miRNAs in UM with Chromosome 3 Aberrations
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miRNAs associated with metastasis in UM
Association of miRNAs with metastasis-free survival is essential for better understanding of miR-
NA’s involvement in UMmicro-metastasis. In a very recent report by Herlihy et al (2015), de-reg-
ulation of genes coding for epigenetic modifiers have been linked with poor prognosis in UMwith
M3/ class 2 [44]. The data derived frommetastasis-free survival analysis is presented in S6 Table
and Fig 5. These results indicate that the expression ofmiR-214,miR-149,miR-146b,miR-199a,
miR-1238 and miR-134 can be used to evaluate the metastasis-free survival in UM patients.miR-
149 andmiR-134 expressions show a statistically significant association with liver metastasis.
The non-availability of 2–5 years clinical follow-up data for some patients in the cohort was
a limitation in this study. We hope further studies with larger sample size and complete clinical
follow-up will be able to determine the panel of miRNAs as metastatic predictors and prognos-
tic indicators.
Supporting Information
S1 Fig. Photomicrographs of chromosome 3 abbrerations by Chromogenic in-situ hybridi-
sation (CISH). The arrow heads indicates the hybridized spots. A: Normal retina with disomy
18 (control). B: Uveal melanoma tumour with monosomy 3, C: Uveal melanoma tumour with
disomy 3.
(TIF)
S2 Fig. Photomicrographs of HSP27 protein expression by Immunohistochemistry. A: Pos-
itive control, High expression of HSP27 protein in the MCF-7 cells (Breast carcinoma cell line);
B: Negative control (performed by the exclusion of primary antibody), Absence of HSP27 pro-
tein in the MCF-7 cells (Breast carcinoma cell line); C & D: High to Moderate expression of
HSP27 in the D3 melanoma tumors; E: Low to Negative expression of HSP27 in the M3 mela-
noma tumors.
(TIF)
Fig 5. Graphical representation of metastasis-free survival was analysed by Kaplan-Meier analysis. The cumulative proportion surviving at end of the
interval (60 months) is represented in percentage. Follow up of 52 patients (2–5 years of duration) were considered in the study.
doi:10.1371/journal.pone.0146128.g005
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S3 Fig. Unsupervised analysis: Hierarchical cluster of the top 100 differentially expressed
miRNAs between M3 and D3 UM primary tumours (FFPE). The green colour indicates the
down-regulated miRNAs while red color indicates the up-regulated miRNAs. The range of the
significant de-regulation is -2.0 to +2.0 log2 ratio.
(TIF)
S1 Table. Clinico-pathological description, chromosome 3 aberration and HSP27 protein
expression in UM tumor tissues.
(DOC)
S2 Table. Details of taqman probes and primers used in qRT-PCR.
(DOC)
S3 Table. Correlation analysis of Chromosome 3 aberration with clinico- pathological
parameters in UM patients.
(DOC)
S4 Table. Correlation analysis of liver metastasis with clinico- pathological parameters in
UM patients.
(DOC)
S5 Table. List of top 10 up-regulated miRNAs obtained by ANOVA and SAM.
(DOC)
S6 Table. Clinico-pathological descriptions of the tumors mean and median fold change of
individual miRNAs, statistical significance (p-value 0.05) derived between the clinico-
pathological parameters and mean fold change of miRNAs expression.
(DOC)
S7 Table. Data of miRNA expressions in UM quantified by qRT-PCR.
(XLS)
S8 Table. Downstream effect analysis of genes and miRNAs over-expressed in UM.
(DOC)
S9 Table. mRNA expression analysis by qRT-PCR.
(DOC)
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